Management of preterm infants with intracardiac thrombi: Use of thrombolytic agents

Pediatric Drugs

Volumn 3, Issue 12, 2001, Pages 883-898

  Rimensberger, Peter C ^a   Humbert, James R ^a   Beghetti, Maurice ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

DRUG EFFICACY; FIBRINOLYTIC THERAPY; HIGH RISK POPULATION; HUMAN; INTRACARDIAC THROMBOSIS; PREMATURITY; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS; THROMBOPHILIA;

EID: 0035690189     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103120-00002     Document Type: Review

References (97)

1. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian registry of VTE
2. Neonatal symptomatic thromboembolism in Germany: Two years survey
3. Neonatal thrombosis: Report of a prospective Canadian and International registry
4. Thrombosis and infection complicating central venous catheterization in neonates
5. Incidence of thrombosis during central venous catheterization of newborns: A prospective study
6. Broviac catheterization in low birth weight infants: Incidence and treatment of associated complications
7. Central venous catheters in low birth weight infants: Incidence of related complications
8. Central catheterization in newborn infants: Incidence of complications over a 1-year period
9. Thrombus detection on central venous catheters in the neonatal intensive care unit
10. Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants
11. Right atrial thrombus formation screening using two-dimensional echocardiograms in neonates with central venous catheters
12. Thrombus associated with central venous catheters in infants and children
13. Complications associated with central venous catheters inserted in critically ill neonates
14. Thrombus formation after umbilical arterial catheterisation: An angiographic study
15. Catheter complications in total parenteral nutrition: A prospective study of 200 consecutive patients
16. Sonographic detection of neonatal umbilical-artery thrombosis: Clinical correlation
17. Neonatal aortic thrombosis: Recent experience
18. Percutaneous central venous catheterisation: Three years' experience in a neonatal intensive care unit
19. Percutaneous central i.v. access in the neonate: Experience with 535 silastic catheters
20. Successful treatment of a right atrial thrombus secondary to central venous catheterisation
21. Thrombus in the right ventricle in an infant: A good result of thrombolytic therapy with recombinant tissue plasminogen activator
22. Central venous line thrombosis in premature infants: A case management and literature review
23. Local low-dose urokinase treatment of acquired intracardiac thrombi in preterm infants
24. Urokinase in a premature infant: Use in right intra-atrial thrombosis due to umbilical vein catheterization
25. Urokinase therapy for a catheter-related right atrial thrombus
26. Right intraventricular thrombus. Rare complication of caval catheterization
27. Successful use of tissue plasminogen activator (t-PA) in catheter-related intracardiac thrombi of two premature infants
28. Treatment of right atrial thrombus with urokinase
29. Surgical therapy of pulmonary thrombosis due to candidiasis in a premature infant
30. Septic atrial thrombosis: A potentially lethal complication of Broviac catheters in infants
31. Candida septicemia and right atrial mass secondary to umbilical vein catheterization
32. Echocardiographic diagnosis of intracardiac thrombi complicating total parenteral nutrition
33. Thrombus in right atrium in two infants successfully treated with tissue plasminogen activator
34. Intracardiac thrombi complicating central total parenteral nutrition: Resolution without surgery or thrombolysis
35. Thrombosis of the right atrium after umbilical venous catheterisation: Favourable outcome after early thrombectomy
36. Right atrial ball valve thrombosis: A complication of central venous alimentation in an infant
37. Right atrial thrombosis in two premature infants: Successful treatment with urokinase and heparin
38. Urokinase therapy for a central venous catheter thrombus
39. Intracardiac thrombus formation with rapidly progressive heart failure in the neonate: Treatment with tissue type plasminogen activator
40. Urokinase therapy in neonates with catheter related central venous thrombosis
41. Early intracardiac thrombosis in preterm infants and thrombolysis with recombinant tissue type plasminogen activator
42. Development of the hemostatic system in the neonate and young infant
43. Inhibition of activated protein C anticoagulant activity by prothrombin
44. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to low plasminogen concentration
45. Histidine-rich gylcoprotein and plasminogen plasma levels in term and preterm newborns
46. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA)
47. Coagulation and fibrinolytic systems in the ill preterm newborn
48. Activation of the plasma clotting, fibrinolytic, and kinin-kallikrein system in preterm infants with severe idiopathic respiratory distress syndrome
49. Aortic and renal artery thrombosis in a neonate: Recovery with thrombolytic therapy
50. Neonatal portal vein thrombosis successfully treated by regional streptokinase infusion
51. Central venous catheter mechanical irritation of the right atrial free wall: A cause for thrombus formation
52. Umbilical artery catheters in the newborn: Effects of heparin
53. Thrombosis: An underestimated complication of central catheters? Subclavian vein, vena cava and renal vein thrombosis after silastic catheters
54. Prolonged bacteremia with catheter-related central venous thrombosis
55. 2-Dimensional echocardiographic diagnosis of an intracardiac thrombus in children
56. Diagnosis and management of catheter-related infected intracardiac thrombosis in premature infants
57. Two dimensional echocardiography in evaluation of right atrial masses: Five cases in pediatric patients
58. Doppler evaluation of central venous lines in the superior vena cava
59. Low-dose fibrinolytic therapy in infants
60. Thrombolysis with low dose tissue plasminogen activator
61. Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator
62. Tissue plasminogen activator: A new thrombolytic agent
63. Thrombolytic therapy: Current status (second of two parts)
64. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: Six years experience and review of the literature
65. Thrombolysis in newborns and infants
66. Failure of systemic thrombolytic and heparin therapy in the treatment of neonatal thrombosis
67. Neonatal thrombosis and the thrombolytic system: Pathophysiology and therapy
68. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system
69. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults
70. Peripheral thrombolysis with tissue plasminogen activator. Results of two treatment regimens
71. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for recombinant tissue-type plasminogen activator
72. Thrombolysis in myocardial infarction (TIMI) trial, phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
73. Tissue plasminogen activator for the treatment of thromboembolism in infants and children
74. Selective clot lysis with low-dose streptokinase
75. Selective streptokinase infusion: Clinical and laboratory correlates
76. Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator
77. Results of 102 cases of complete repair of congenital heart defects in patients weighing 700 to 2500 grams
78. The outcome of cardiac operations in infants weighing two kilograms or less
79. Surgical management of active infective endocarditis in a premature neonate weighing 950 grams
80. Venous thromboembolism complications in children: A critical review of the literature
81. Antithrombotic therapy in children
82. Anticoagulant therapy by continuous heparinization in newborn and older infants
83. Inherited antithrombin III deficiency in the neonate
84. Efficacy and safety of heparin anticoagulation for neonatal renal vein thrombosis
85. Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study
86. Heparin clearance in the newborn
87. Venous thromboembolic events in pediatric patients: Diagnosis and management
88. Low-molecular-weight heparin for venous thrombosis in a neonate
89. Evaluation and treatment of thrombosis in the neonatal intensive care unit
90. Use of enoxaparin in a preterm infant
91. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology
92. Thrombophilia in infantile thromboses
93. Congenital thrombophilia
94. Neonatal symptomatic thromboembolism in Germany
95. The clinical outcome after inferior vena cava thrombosis in early infancy
96. Coagulation-associated complications of indwelling arterial and central venous catheters during heparin prophylaxis: A prospective study
97. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children